Top Markets
#1 Islamic Coin Islamic Coin +154.50%
#2 PulseChain PulseChain +49.22%
#3 RedStone RedStone +23.91%
#4 MarsCoin MarsCoin +12.77%
#5 Nockchain Nockchain +12.59%
#6 BOOK OF MEME BOOK OF MEME +11.85%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.84%
#8 SkyAI SkyAI +8.96%
#9 Lighter Lighter +8.81%
#10 Monad Monad +8.69%
Coin of the day
Islamic Coin Islamic Coin
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Immunotech Biopharm Ltd Immunotech Biopharm Ltd

Immunotech Biopharm Ltd

6978
Classement en actions #27877
Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in... Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in cellular immunotherapy. Its primary activities involve the investigation, development, and market introduction of T cell-based immunotherapy solutions for various cancers within the People's Republic of China. The company's flagship product, EAL, is a multi-target cellular immunotherapy currently undergoing Phase II clinical trials for the purpose of preventing liver cancer recurrence after surgery. Furthermore, Immunotech Biopharm is conducting both preclinical and clinical research on EAL for its potential use in treating lung cancer, glioma, gastric cancer, and colorectal cancer. Other pipeline assets include the 6B11-OCIK injection, which is in Phase I trials for ovarian cancer; the CAR-T-19 injection product, targeting B-cell acute lymphoblastic leukaemia; and a range of TCR-T cell products designed for solid tumor treatment. Established in 2006, the company's main office is located in Beijing, China.
Prix de l'action
$0.04861197
Capitalisation boursière
$30.02M
Changement (1 jour)
0.00%
Changement (1 an)
-91.39%
Pays
CN
Échange Immunotech Biopharm Ltd (6978)

Catégorie

Healthcare
Bénéfices pour Immunotech Biopharm Ltd (6978)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Immunotech Biopharm Ltd, les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Immunotech Biopharm Ltd de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH